Trial Profile
Comparison of bleeding risk among elderly patients and overall non-valvular atrial fibrillation patients treated with apixaban, dabigatran, rivaroxaban and warfarin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Apr 2017
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Warfarin
- Indications Stroke
- Focus Therapeutic Use
- 18 Apr 2017 New trial record